These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24897088)

  • 21. Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides.
    Drognitz O; Thorn D; Krüger T; Gatermann SG; Iven H; Bruch HP; Muhl E
    Infection; 2006 Feb; 34(1):29-34. PubMed ID: 16501900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glycopeptides (vancomycin, teicoplanin)].
    Furuta I; Kitahashi T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():423-6. PubMed ID: 15658354
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibiotics.
    Dalal KS; Bridgeman MB
    Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
    [No Abstract]   [Full Text] [Related]  

  • 25. [Glycopeptides].
    Hayashi I
    Nihon Rinsho; 2001 Apr; 59(4):761-70. PubMed ID: 11305003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
    Hussar DA; Nguyen A
    J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
    [No Abstract]   [Full Text] [Related]  

  • 28. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of linezolid and vancomycin treatment on local signs and symptoms of inflammation among pediatric patients with complicated skin and skin structure infections.
    Deville JG; Equils O; Huang DB; Ang JY
    Clin Pediatr (Phila); 2011 Nov; 50(11):1064-7. PubMed ID: 21098522
    [No Abstract]   [Full Text] [Related]  

  • 31. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Glycopeptide antibiotics: eremomycin, vancomycin, and teicoplanin. Comparison of several parameters of pharmacokinetics and antimicrobial activity].
    Filippos'iants ST; Malkova IV; Gol'dberg LE
    Antibiot Khimioter; 1989 Jul; 34(7):523-6. PubMed ID: 2530944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
    Bouza E; Rodríguez-Créixems M; Muñoz P
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():52-8. PubMed ID: 9441324
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA approves Dalvance to treat skin infections.
    Clin Infect Dis; 2014 Jul; 59(2):i. PubMed ID: 25105184
    [No Abstract]   [Full Text] [Related]  

  • 36. Dalbavancin approved for acute skin infections.
    Traynor K
    Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
    [No Abstract]   [Full Text] [Related]  

  • 37. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
    Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
    Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological considerations in the economic evaluation of glycopeptides].
    García-Quetglas E; Sádaba B; Honorato J
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():68-73. PubMed ID: 9441326
    [No Abstract]   [Full Text] [Related]  

  • 39. [Streptogramins and glycopeptides].
    Tsuji A
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():360-6. PubMed ID: 17455646
    [No Abstract]   [Full Text] [Related]  

  • 40. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
    Dunne MW; Zhou M; Darpo B
    Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.